Wugen to Initiate a Pivotal Trial for Its Investigational

Wugen to Initiate a Pivotal Trial for Its Investigational, - GlobeNewswire

Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007...

Press Releases | Wugen

Press Releases · Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients ...

Wugen: Home

LATEST NEWS · Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients ...

Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf ...

Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, ... · This page requires Javascript. · Tags.

Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer ...

“Cherry joins Wugen at our most critical inflection point yet, as we prepare to begin our Phase 2 pivotal trial for WU-CART-007, the first CD7- ...

Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer ...

"Cherry joins Wugen at our most critical inflection point yet, as we prepare to begin our Phase 2 pivotal trial for WU-CART-007, the first CD7- ...

Wugen-to-Initiate-a-Pivotal-Trial-for-Its-Investigational ... - Larvol Delta

WU CART 007 - Wugen. https://www.globenewswire.com/news-release/2024/11/12/2978872/0/en/Wugen-to-Initiate-a-Pivotal-Trial-for-Its- ...

Phase 2 Findings Show Wugen's Investigational Allogeneic CAR-T ...

Louis, Wugen, Inc. is a clinical-stage U.S. biotechnology company developing the next generation of off-the-shelf CAR-T and memory natural ...

Clinical Trials | Wugen

WU-CART-007 is an investigational, off the shelf, fratricide-resistant allogeneic CD7 targeted CAR-T cell being evaluated in a Phase 1/2 study.

Phase 2 Findings Show Wugen's Investigational Allogeneic

-- U.S. Biotech Wugen to Initiate Follow-Up Study Exploring Its Anti-CD7, Off-the-Shelf, Allogeneic CAR-T Cell Therapy in Pediatric and ...

Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101 ...

Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with ...

BioGenerator-backed Wugen, which has raised $200M+ in ... - BioSTL

Louis-based clinical-stage biotechnology startup Wugen, which has raised more than $200 million in venture funding, has launched a clinical trial for one of its ...

Wugen to Present New Clinical Data for WU-CART-007 and ...

Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies ...

MaxCyte and Wugen Sign Strategic Platform License to Expedite ...

Wugen's lead program is evaluating WU-CART-007, a CD7 targeted CAR-T cell therapy, in a global Phase 1/2 clinical trial for the treatment of ...

Wugen Announces RMAT and PRIME Designations for WU-CART ...

... its Investigational Memory Natural Killer Cell Therapy, at EHA ... trials and begin pivotal studies later this year.” ... Wugen is applying its proprietary ...

Wugen Raises $172 Million to Advance Clinical Stage Memory NK ...

Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications.

Finding a Clinical Trial | National Institutes of Health (NIH)

Front entrance of the Mark O. Hatfield Clinical Research Center. ... The NIH maintains an online database of clinical research studies taking place at its ...

Wugen doses first patient in AML therapy trial

Wugen has dosed the first patient in a Phase I clinical trial of ... The global, open-label, dose-escalation and cohort expansion study ...

MaxCyte and Wugen Sign Strategic Platform License to Expedite ...

Wugen's lead program is evaluating WU-CART-007, a CD7 targeted CAR-T cell therapy, in a global Phase 1/2 clinical trial for the treatment of ...

Wugen - LinkedIn

Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.